# Survival Curves Projection and Benefit Time Points Estimation using a New Statistical Method

## Authors

• Toni Monleón-Getino Section of Statistics, Department of Genetics, Microbiology and Statistics. University of Barcelona, Spain

## Keywords:

Survival function, projection, Weibull growth curve, non linear regression

## Abstract

Survival analysis concerns the analysis of time-to-event data and it is essential to study in fields such as oncology, the survival function, S(t), calculation is usually used, but in the presence of competing risks (presence of competing events), is necessary introduce other statistical concepts and methods, as is the Cumulative incidence function CI(t). This is defined as the proportion of subjects with an event time less than or equal to. The present study describe a methodology that enables to obtain numerically a shape of CI(t) curves and estimate the benefit time points (BTP) as the time (t) when a 90, 95 or 99% is reached for the maximum value of CI(t). Once you get the numerical function of CI(t), it can be projected for an infinite time, with all the limitations that it entails. To do this task the R function Weibull.cumulative.incidence() is proposed. In a first step these function transforms the survival function (S(t)) obtained using the Kaplan–Meier method to CI(t). In a second step the best fit function of CI(t) is calculated in order to estimate BTP using two procedures, 1) Parametric function: estimates a Weibull growth curve of 4 parameters by means a non-linear regression (nls) procedure or 2) Non parametric method: using Local Polynomial Regression (LPR) or LOESS fitting. Two examples are presented and developed using Weibull.cumulative.incidence() function in order to present the method. The methodology presented will be useful for performing better tracking of the evolution of the diseases (especially in the case of the presence of competitive risks), project time to infinity and it is possible that this methodology can help identify the causes of current trends in diseases like cancer. We think that BTP points can be important in large diseases like cardiac illness or cancer to seek the inflection point of the disease, treatment associate or speculate how is the course of the disease and change the treatments at those points. These points can be important to take medical decisions furthermore.

## References

Kalbfleisch JD, Prentice RL. Competing Risks and Multistate Models. The Statistical Analysis of Failure Time Data. Second Edition. New York: Hoboken, N.J.: J. Wiley,; 2002.

Dodge Y. The Oxford Dictionary of Statistical Terms. OUP Oxford 2003.

Dutza A, Löck S. Competing risks in survival data analysis. Radiotherapy and Oncology. 2019;130:185–189.

Columbia-University-MSPH. Competing Risk Analysis Tutorial from Population Health Methods. Population Health Methods; 2020. Available from: https://www.mailman.columbia.edu/research/population-health-methods/competing-risk-analysis.

Prentice RL, Kalbfleisch JD, Peterson AV, Jr NF, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34(4):541–554.

Armitage P, Berry G, Matthews J. Clinical trials.Statistical methods in medical research. 4th ed. Oxford (UK): Blackwell Science; 2001.

Lee ET, Wang JW. Statistical methods for survival data analysis. Wiley; 2003.

Klein JP, Moeschberger ML. Survival Analysis Techniques for Censored and truncated data. Springer; 1997.

Bintu NS. A comparison of Kaplan–Meier and cumulative incidence estimate in the presence or absence of competing risk in breast cancer. University of Pittsburgh, 2004 . Thesis.; 2004.

Kaplan E, Meier P. Non-parametric estimation from incomplete observations. Journal of the American Statistical Association. 1958;53:457–481.

R-Core-Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.; 2013. Available from: http://www.R-project.org/.

Gaynor JJ, Feuer EJ. On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples From Clinical

Oncology Data. Journal of the American Statistical Association. 1993;88(422):400–409.

Bryant J, Dignam JJ. Semiparametric models for cumulative incidence functions. Biometrics. 2004;60(1):182–190.

Scheike TH, Zhang MJ. Flexible competing risks regression modeling and goodness-of-fit. Lifetime Data Anal. 2008;14(4):464–483.

Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. The Stata Journal. 2004;4:103–112.

Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association. 1999;94:496–509.

Weona BM, Jeb JH. Trends in scale and shape of survival curves. Sci Rep. 2012;2:504.

Mendez J, Monleon-Getino A, Jofre J, Lucena F. Use of non-linear mixed-effects modelling and regression analysis to predict the number of somatic coliphages by plaque enumeration after 3 hours of incubation. Journal of water and health. 2017;15(5):706–717.

Monleón-Getino T. BDSbiost3: Machine learning and advanced statistical methods for omic, categorical analysis and others; 2020. Available from: https://github.com/amonleong/BDSbiost3.

Fox J. Nonparametric Regression in R: An Appendix to An R Companion to Applied Regression 2nd edition; 2010.

2020-05-09

## How to Cite

Monleón-Getino, T. . (2020). Survival Curves Projection and Benefit Time Points Estimation using a New Statistical Method. International Journal of Statistics in Medical Research, 9, 28–40. https://doi.org/10.6000/1929-6029.2020.09.04

General Articles